sever
acut
respiratori
syndrom
sar
coronaviru
cov
identifi
etiolog
agent
acut
respiratori
diseas
caus
atyp
pneumonia
diarrhea
high
mortal
differ
type
sarscov
vaccin
includ
nonrepl
vector
vaccin
develop
administr
vaccin
anim
model
system
shown
promis
gener
efficaci
safe
vaccin
nevertheless
identif
side
effect
preferenti
elderli
anim
model
indic
need
develop
novel
vaccin
test
improv
anim
model
system
live
attenu
virus
gener
proven
effect
vaccin
viral
infect
limit
number
sarscov
attenu
modif
describ
includ
mutat
partial
complet
gene
delet
affect
replicas
like
nonstructur
protein
structur
gene
drastic
chang
sequenc
regul
express
viral
subgenom
mrna
promis
vaccin
candid
develop
laboratori
base
delet
envelop
e
gene
alon
combin
remov
six
addit
gene
nonessenti
viru
replic
virus
lack
e
protein
attenu
grew
lung
provid
homolog
heterolog
protect
improv
vaccin
candid
direct
toward
increas
viru
titer
use
power
virus
mutat
phenotyp
maintain
attenu
phenotyp
safeti
live
sarscov
vaccin
increas
insert
complementari
modif
gene
gene
scrambl
prevent
rescu
virul
phenotyp
recombin
remodel
vaccin
genom
base
codon
deoptim
use
synthet
biolog
newli
gener
vaccin
experiment
vaccin
fulli
reproduc
clinic
sign
observ
natur
host
addit
except
evalu
vaccin
made
young
anim
shown
outcom
challeng
experi
although
posit
young
anim
frequent
show
side
effect
perform
old
mice
recent
anim
model
consider
improv
reproduc
patholog
observ
human
particular
mouseadapt
sarscov
model
select
fifteen
passag
mice
reproduc
clinic
sign
observ
human
infect
sar
epidem
includ
death
infect
mice
anim
model
consid
best
avail
therefor
vaccin
candid
develop
far
may
reevalu
model
use
young
age
mice
vaccin
base
whole
purifi
inactiv
viru
benefit
present
complet
repertoir
viral
antigen
although
inactiv
vaccin
gener
provid
longlast
immun
vaccin
provid
good
protect
mice
hamster
partial
protect
ferret
rhesu
monkey
formaldehydeinactiv
sarscov
vaccin
show
partial
protect
inactiv
sarscov
vaccin
also
administ
human
vaccin
safe
induc
neutral
antibodi
efficaci
data
report
overal
inactiv
vaccin
base
whole
purifi
viru
induc
neutral
antibodi
appar
safe
least
young
anim
model
provid
good
protect
subunit
vaccin
advantag
simplic
chemic
definit
lack
potenti
variabl
case
sarscov
great
advantag
welldefin
protein
domain
bind
cell
receptor
human
angiotensin
convert
enzym
provid
full
immun
protect
concept
reinforc
observ
monoclon
antibodi
specif
receptor
bind
domain
elicit
protect
sever
anim
model
includ
african
green
monkey
addit
proteinderiv
domain
peptid
protein
larg
protein
sarscov
expos
envelop
also
elicit
viru
neutral
antibodi
could
use
improv
subunit
vaccin
furthermor
immun
sarscov
also
demonstr
viruslik
particl
vlp
overal
result
obtain
subunit
vaccin
strongli
suggest
protect
sar
vaccin
feasibl
dna
vaccin
safe
nonexpens
often
effici
larg
mammal
dna
vaccin
induc
sarscov
neutral
antibodi
protect
mice
use
viral
vector
protect
sar
extens
explor
adenoviru
induc
good
protect
mice
modifi
vaccinia
ankara
mva
provid
protect
mice
ferret
although
induct
antibodydepend
enhanc
diseas
ade
report
adenoassoci
viru
induc
longterm
protect
sarscov
parainfluenza
viru
elicit
protect
hamster
monkey
recombin
measl
virus
express
protein
sarscov
induc
neutral
antibodi
immun
respons
sarscov
newcastl
diseas
recombin
viru
express
protein
sarscov
induc
neutral
antibodi
african
green
monkey
immun
via
respiratori
tract
recombin
attenu
vesicular
stomat
viru
vsv
protect
mice
sarscov
challeng
month
vaccin
venezuelan
equin
enceph
vee
viru
express
protein
sarscov
induc
protect
challeng
virul
viru
mous
model
overal
result
indic
good
prospect
develop
efficaci
safe
vaccin
prevent
sar
nevertheless
relev
aspect
need
improv
order
achiev
vaccin
fulli
protect
free
side
effect
young
elderli
peopl
sarscov
envelop
singlestrand
positivesens
rna
viru
genom
kb
belong
genu
b
coronavirida
fig
replicas
gene
encod
within
twothird
sarscov
genom
includ
two
overlap
open
read
frame
orf
name
orf
latter
translat
ribosom
frameshift
upstream
orf
stop
codon
fig
translat
orf
cytoplasm
infect
cell
result
synthesi
two
polyprotein
process
two
viral
proteinas
yield
function
nonstructur
protein
nsp
nsp
compon
membraneanchor
replicationtranscript
complex
cov
encod
speciesspecif
accessori
gene
downstream
orf
remark
conserv
order
replicasetranscriptas
spike
envelop
e
membran
nucleocapsid
n
lipid
bilay
envelop
contain
least
three
protein
e
coordin
virion
assembl
releas
larg
peplom
fig
glycoprotein
locat
virion
surfac
confer
viru
characterist
corona
shape
main
mediat
host
cell
attach
entri
sarscov
orf
encod
addit
viru
membran
protein
accessori
protein
function
accessori
protein
still
unclear
howev
known
protein
influenc
virushost
interact
viral
pathogenesi
sarscov
molecul
serv
receptor
also
implic
altern
receptor
entri
live
attenu
virus
gener
proven
effect
vaccin
viral
infect
product
effect
safe
live
attenu
vaccin
anim
cov
satisfactori
larg
vaccin
strain
insuffici
immunogen
addit
may
recombin
result
novel
virus
increas
virul
sever
group
includ
describ
modif
sarscov
attenu
domest
virus
may
use
platform
develop
inactiv
live
vaccin
gener
rna
virus
essenti
develop
revers
genet
system
develop
viru
attenu
phenotyp
certainli
case
coronavirus
largest
genom
known
around
kb
rna
viru
increas
technic
difficulti
gener
infecti
cdna
develop
effici
transmiss
gastroenter
cov
tgev
sarscov
revers
genet
system
insert
infecti
cdna
clone
virus
bacteri
artifici
chromosom
bac
fig
system
genom
rna
express
cell
nucleu
control
cytomegaloviru
promot
first
amplif
cellular
polymeras
ii
subsequ
amplif
cytoplasm
viral
rnadepend
rna
polymeras
revers
genet
system
highli
effici
impli
two
amplif
step
addit
cdna
stabil
bac
high
soon
bac
technolog
appli
assembl
infecti
coronaviru
cdna
clone
altern
strategi
develop
includ
system
assembl
fulllength
cdna
construct
tgev
genom
use
adjoin
cdna
subclon
uniqu
flank
interconnect
junction
transcript
deriv
tgev
cdna
assembl
use
approach
use
deriv
infecti
recombin
viru
system
clone
vector
poxviru
use
genom
poxviru
includ
genom
cdna
copi
templat
viral
genom
transcrib
vitro
infecti
viru
recov
transfect
cell
modifi
procedur
describ
coronaviru
genom
rna
transcrib
insid
cell
use
poxviru
genom
templat
end
viral
genom
clone
control
promot
poxviru
dna
includ
infecti
cdna
transfect
cell
infect
poxviru
express
polymeras
gener
transcript
reconstitut
infecti
cov
case
sarscov
sever
gene
delet
order
gener
virus
attenu
phenotyp
nevertheless
delet
one
accessori
gene
significantli
attenu
sarscov
fortun
show
delet
e
gene
encod
envelop
protein
led
viabl
sarscov
indic
e
protein
essenti
viru
replic
interestingli
virus
tabl
gene
delet
three
sarscov
recombin
virus
delet
mutant
without
e
gene
led
virus
attenu
phenotyp
lack
e
protein
attenu
grow
lung
immunogen
differ
anim
model
modif
delet
sarscov
gene
also
consid
design
vaccin
prevent
sar
gene
n
essenti
viru
replic
other
nonessenti
viru
growth
cell
cultur
vivo
design
sar
vaccin
base
delet
sarscov
gene
describ
nevertheless
attent
given
delet
modif
e
gene
sarscov
delet
mutant
lack
orf
significantli
influenc
vitro
vivo
replic
effici
mous
model
recombin
virus
replic
similar
wildtyp
level
suggest
either
groupspecif
orf
play
limit
role
vivo
replic
effici
mous
model
use
evalu
meet
requir
discrimin
activ
groupspecif
orf
diseas
fact
unexpect
delet
orf
encod
structur
protein
would
show
littl
influenc
viru
replic
mous
model
delet
orf
show
minor
decreas
tenfold
viru
growth
furthermor
delet
combin
gene
delet
orf
show
titer
reduct
vero
cell
show
limit
effect
viru
growth
murin
model
day
postinfect
moreov
simultan
delet
larger
combin
groupspecif
gene
led
product
infecti
sarscov
delet
mutant
propag
cell
cultur
titer
similar
parent
wildtyp
viru
attenu
transgen
mice
express
sarscov
receptor
therefor
effect
sarscov
gene
delet
need
test
relev
anim
model
interestingli
delet
e
gene
alon
combin
remov
gene
led
mutant
virus
seem
promis
vaccin
candid
describ
next
e
gene
nonessenti
genu
b
mhv
cov
although
elimin
gene
mhv
genom
reduc
viru
growth
cell
cultur
contrast
group
tgev
coronaviru
express
e
gene
product
essenti
viru
releas
spread
propag
e
genedelet
tgev
tgevd
restor
provid
e
protein
tran
recombin
sarscov
rsarscov
lack
e
gene
gener
bac
fig
recov
vero
cell
rel
high
titer
around
pfuml
also
cell
low
titer
indic
sarscov
e
protein
essenti
viru
replic
cell
cultur
electron
microscopi
observ
vero
cell
infect
sarscov
wt
de
delet
mutant
show
higher
effici
assembl
releas
wt
viru
fig
respect
sarscovd
behav
like
mhv
although
sarscovd
grow
consider
higher
titer
vaccin
viabil
efficaci
requir
product
virus
high
titer
interestingli
adapt
rsarscovd
viru
grow
vero
cell
passag
led
increas
viru
titer
reach
valu
almost
ident
display
fulllength
viru
around
pfuml
titer
close
requir
competit
live
attenu
vaccin
sarscov
infect
replic
sever
speci
includ
mice
ferret
hamster
nonhuman
primat
anim
develop
inappar
mild
diseas
ideal
anim
model
complet
reproduc
human
cell
infect
wt
viru
virion
final
bud
step
found
bound
cell
wherea
e
proteindelet
virus
number
increas
suggest
absenc
e
protein
led
delay
pinchoff
step
clinic
diseas
patholog
find
identifi
evalu
rsarscovd
vaccin
candid
use
three
anim
model
system
hamster
transgen
mice
express
receptor
human
sarscov
convent
mice
challeng
mouseadapt
viru
anim
model
system
complementari
hamster
model
use
studi
sarscovd
viru
pathogen
demonstr
element
present
human
case
sarscov
infect
includ
interstiti
pneumon
consolid
hamster
model
reproduc
support
sarscov
replic
respiratori
tract
higher
titer
longer
durat
mice
nonhuman
primat
viru
replic
model
accompani
histolog
evid
pneumon
anim
develop
viremia
extrapulmonari
spread
viru
although
overt
clinic
diseas
absent
hamster
model
use
model
evalu
sarscov
infect
titer
recombin
sarscov
rsarscov
achiev
respiratori
tract
hamster
similar
previous
report
wildtyp
viru
least
higher
titer
rsarscovd
viru
suggest
mutant
viru
attenu
histopatholog
examin
lung
infect
hamster
show
reduc
amount
viral
antigen
pulmonari
inflamm
rsarscovd
infect
rsarscov
infect
anim
indic
rsarscovd
attenu
vivo
fact
reduct
sarscov
titer
patient
associ
consider
reduct
pathogen
increas
surviv
rate
rsarscovd
immun
hamster
remain
activ
follow
wildtyp
viru
challeng
mock
immun
display
decreas
activ
transgen
mice
model
base
product
mice
express
receptor
human
sarscov
transgen
mice
model
obtain
differ
laboratori
express
control
differ
promot
mice
develop
moder
respiratori
diseas
overwhelm
neurolog
diseas
mortal
intranas
infect
sarscov
use
assess
attenu
vaccin
safeti
efficaci
previous
show
infect
highli
suscept
mice
rsarscovd
rsarscov
e
sever
groupspecif
protein
gene
delet
rsarscov
result
neither
weight
loss
death
even
inocul
high
viru
dose
mouseadapt
sarscov
model
use
evalu
rsarscovd
rsarscovd
base
recent
isol
sarscov
adapt
growth
mice
rat
model
provid
use
system
vaccin
evalu
strain
mice
rat
infect
virus
develop
sever
respiratori
diseas
even
death
mouseadapt
strain
isol
passag
lung
balbc
mice
strain
unlik
parent
urbani
strain
viru
intranas
inocul
viru
result
sign
respiratori
diseas
substanti
mortal
show
immun
rsarscovd
sarscovd
almost
complet
protect
balbc
mice
fatal
respiratori
diseas
caus
mouseadapt
sarscov
fig
partli
protect
transgen
mice
lethal
diseas
summari
immunogen
protect
efficaci
rsarscovd
shown
three
anim
model
system
describ
hamster
highli
suscept
transgen
mice
express
receptor
human
sarscov
convent
mice
challeng
viru
interestingli
homolog
heterolog
protect
observ
fact
hamster
transgen
mice
immun
rsarscovd
develop
high
serum
neutral
antibodi
titer
protect
replic
homolog
sarscov
urbani
heterolog
sarscov
upper
lower
respiratori
tract
relev
observ
strain
sarscov
one
serolog
diverg
human
sarscov
identifi
relat
urbani
strain
addit
shown
strain
close
relat
isol
obtain
anim
sarscov
reemerg
would
probabl
anim
origin
despit
attenu
replic
respiratori
tract
rsarscovd
viru
immunogen
efficaci
vaccin
hamster
two
mous
model
virul
perform
hamster
use
activ
wheel
decreas
hamster
activ
detect
day
hamster
infect
sarscov
lack
e
gene
contrast
infect
viru
fulllength
genom
furthermor
rsarscovd
infect
brain
infect
transgen
mice
contrast
wt
viru
overal
data
indic
e
virul
gene
potenti
mechan
e
gene
product
virul
investig
laboratori
shown
express
e
gene
drastic
reduc
express
gene
involv
stress
unfold
protein
respons
reduct
stress
respons
associ
decreas
innat
specif
immun
respons
consequ
postul
delet
e
gene
lead
increas
immun
respons
viru
reduc
appar
pathogen
three
complementari
strategi
appli
improv
rsarscovd
vaccin
gener
effici
inactiv
live
modifi
vaccin
viru
titer
need
high
order
obtain
econom
competit
vaccin
increas
viru
titer
propos
novel
approach
base
previou
find
show
coronaviru
genom
encod
mutat
exonucleas
exon
display
mutat
phenotyp
engin
sarscov
mutat
delet
e
protein
modifi
includ
exon
caus
accumul
mutat
throughout
viral
genom
mutat
virus
pass
cell
cultur
infect
cell
highest
viru
dilut
possibl
dilut
contain
mutant
virus
highest
titer
therefor
expect
serial
passag
dilut
select
viru
clone
high
titer
desir
viru
titer
achiev
confirm
high
titer
virus
still
attenu
vivo
viru
evolut
revert
standard
level
replac
mutat
nativ
one
use
infecti
cdna
clone
select
virus
test
protect
previous
describ
previous
shown
rsarscovd
elicit
protect
immun
respons
time
other
also
shown
possibl
delet
addit
nonessenti
gene
gener
viabl
sarscov
addit
delet
gene
involv
inhibit
ifn
activ
propos
delet
gene
determin
whether
remov
increas
immun
respons
vaccin
candid
sarscov
e
protein
reduc
stress
unfold
protein
immun
respons
viru
postul
effort
enhanc
assembl
level
viral
protein
without
diminish
stress
respons
increas
absenc
e
might
increas
immunogen
without
compromis
safeti
consequ
propos
construct
rsarscov
mutant
modifi
e
protein
e
elicit
higher
immun
respons
viru
rsarscovd
mutant
e
code
gene
fulli
function
viru
morphogenesi
insert
within
viral
genom
approach
base
previou
identif
host
protein
bind
sarscov
e
protein
influenc
virusinduc
stress
respons
immun
respons
viru
e
protein
ligand
identifi
coimmun
precipit
mass
spectrometri
studi
previous
report
yeast
twohybrid
technolog
effect
protein
stress
immun
respons
identifi
propos
modifi
specif
e
protein
domain
order
prevent
virushost
cell
interact
counteract
induct
strong
immun
respons
rsarscov
vaccin
focu
modif
three
sarscov
protein
previou
find
protein
indic
fulli
essenti
viru
viabil
modif
may
lead
attenu
virus
experiment
inform
influenc
coronaviru
replicas
protein
modif
attenu
obtain
chang
case
sarscov
shown
significantli
inhibit
ifndepend
signal
decreas
phosphoryl
level
littl
effect
modif
sarscov
mutat
result
viru
replic
effici
wildtyp
viru
cell
defect
ifn
respons
replic
strongli
attenu
cell
intact
ifn
respons
thu
like
mutant
lose
virul
reduc
pathogen
altern
mutat
delet
gene
could
introduc
similar
describ
mhv
replicas
led
attenu
cov
phenotyp
type
mutant
could
investig
relev
gener
attenu
sarscov
phenotyp
could
test
vaccin
candid
delet
mhv
sarscov
virus
caus
reduct
peak
titer
singlecycl
growth
assay
well
reduct
viral
rna
synthesi
growth
find
indic
essenti
viru
replic
delet
may
lead
virus
attenu
phenotyp
addit
recent
studi
mhv
suggest
protein
may
function
pathogenesi
therefor
seem
promis
candid
complement
safeti
rsarscovd
vaccin
oglycosyl
accessori
protein
amino
acid
form
k
permeabl
channellik
structur
essenti
growth
tissu
cultur
cell
delet
gene
lead
small
reduct
viru
titer
reduct
vitro
vivo
protein
may
also
involv
trigger
high
level
proinflammatori
cytokin
chemokin
product
delet
may
reduc
sarscov
virul
gene
map
distal
posit
gene
therefor
recombin
event
restor
wild
phenotyp
gene
gene
one
event
seem
unlik
coronaviru
transcript
regul
highli
conserv
sequenc
preced
gene
transcript
regulatori
sequenc
trss
almost
ident
sequenc
locat
end
genom
downstream
leader
sequenc
tr
preced
gene
encod
complementari
sequenc
newli
synthes
rna
neg
polar
rna
hybrid
tr
locat
next
leader
process
discontinu
rna
synthesi
typic
cov
altern
approach
develop
safer
recombinationresist
live
coronaviru
vaccin
develop
baric
group
novel
procedur
involv
modif
trss
sarscov
vaccin
strain
sequenc
incompat
tr
known
circul
cov
postul
recombin
event
wt
coronavirus
tr
remodel
sarscov
would
result
genom
contain
incompat
mix
regulatori
sequenc
block
express
subgenom
mrna
use
molecular
clone
sarscov
tr
network
remodel
acgaac
ccggat
rewir
genom
transcript
network
allow
effici
replic
mutant
viru
icsarscrg
icsarscrg
recombin
viru
replic
titer
equival
wt
viru
express
typic
ratio
subgenom
mrna
protein
shown
vaccin
candid
provid
protect
challeng
virul
sarscov
previou
studi
use
anim
cov
provid
experiment
evid
humor
cellmedi
respons
anim
coronavirus
exacerb
diseas
previous
summar
safeti
concern
increas
case
sarscov
two
studi
one
report
antibodi
neutral
human
sarscov
also
enhanc
viru
entri
mediat
two
civet
cat
sarscov
virus
glycoprotein
relat
sarscov
isol
second
report
shown
administr
mvabas
sarscov
vaccin
ferret
mva
alon
follow
live
sarscov
challeng
result
enhanc
hepat
nevertheless
side
effect
describ
studi
sarscov
mice
hamster
ferret
african
green
monkey
gener
immun
vaccin
candid
result
absenc
side
effect
nevertheless
still
three
concern
remain
unaddress
one
specif
viral
protein
sarscov
n
express
venezuelan
equin
enceph
vee
viru
vector
result
enhanc
immunopatholog
follow
viral
challeng
similar
immun
patholog
observ
follow
vaccin
formalininactiv
respiratori
syncyti
viru
rsv
second
main
concern
observ
sarscov
vaccin
provid
protect
absenc
side
effect
young
mice
show
immunopatholog
complic
age
mice
third
consider
vaccin
candid
test
anim
model
fulli
reproduc
clinic
symptom
observ
human
one
except
phase
clinic
trial
human
perform
therefor
sar
vaccin
candid
would
requir
addit
rigor
clinic
immunolog
evalu
use
sarscov
mouseadapt
viru
model
potenti
side
effect
assess
young
age
anim
live
viru
vaccin
formul
includ
ration
approach
minim
potenti
revers
wt
phenotyp
simultan
resist
recombin
repair
principl
combin
sarscov
genom
modif
could
lead
virus
attenu
phenotyp
could
consid
safe
effect
vaccin
candid
rsarscovd
select
rsarscov
attenu
principl
revers
virul
phenotyp
could
take
place
reintroduct
e
gene
viru
recombin
close
relat
coronaviru
present
environ
furthermor
exclud
compensatori
mutat
increas
viru
fit
could
caus
revers
virul
phenotyp
minim
possibl
addit
modif
introduc
final
vaccin
candid
includ
modif
orf
encod
protein
describ
advantag
combin
delet
mutat
e
protein
orf
resid
gene
map
distal
posit
genom
kb
separ
make
unlik
singl
recombin
event
could
restor
wt
viru
phenotyp
addit
creativ
reorgan
viru
genom
describ
could
increas
sarscov
safeti
describ
cov
characterist
strictli
conserv
genom
organ
gene
occur
order
mhv
viru
mutant
gene
encod
structur
protein
locat
differ
order
construct
shown
canon
coronaviru
genom
organ
essenti
vivo
replic
mutant
show
attenu
phenotyp
interestingli
rearrang
viral
gene
may
use
gener
cov
reduc
risk
gener
viabl
virus
recombin
circul
field
virus
fact
potenti
recombin
virus
differ
gene
order
like
lead
nonviabl
virus
lack
essenti
gene
result
degeneraci
genet
code
two
amino
acid
protein
code
sequenc
encod
one
synonym
codon
frequenc
synonym
codon
use
amino
acid
unequ
coevolv
cell
translat
machineri
avoid
excess
use
suboptim
codon
often
correspond
rare
otherwis
disadvantag
trna
result
phenomenon
term
synonym
codon
bia
vari
greatli
evolutionarili
distant
speci
codon
optim
recombin
method
wide
use
improv
crossspeci
express
opposit
direct
reduc
express
intent
introduct
suboptim
synonym
codon
seldom
chosen
de
novo
gene
synthesi
aim
design
stabli
attenu
poliovirus
sarscov
novel
strategi
construct
viru
variant
contain
synthet
replac
viru
code
sequenc
deoptim
synonym
codon
usag
infect
equal
amount
polioviru
particl
reveal
neuroattenu
phenotyp
strike
reduct
specif
infect
polioviru
particl
similar
attempt
made
baric
group
design
sarscov
vaccin
vaccin
candid
provid
protect
mous
model
system
challeng
virul
viru
ralph
baric
person
commun
due
distribut
effect
mani
silent
mutat
larg
genom
segment
codondeoptim
virus
genet
stabl
phenotyp
may
prove
suitabl
attenu
substrat
product
vaccin
product
effect
safe
vaccin
anim
coronavirus
previous
report
satisfactori
contrast
product
inactiv
subunit
vaccin
base
dna
recombin
vector
vaccin
gener
revers
genet
use
sarscov
genom
seem
promis
vaccin
candid
need
test
sarscov
mouseadapt
model
macaqu
case
use
young
age
anim
later
absenc
side
effect
safeti
assess
human
phase
clinic
trial
vaccin
manufactur
tendenc
use
welldefin
inactiv
vaccin
unfortun
approach
limit
efficaci
elicit
immun
respons
rel
short
immunolog
memori
possibl
balanc
efficaci
safeti
develop
rna
replicationcompet
propagationdefect
vaccin
candid
base
viral
replicon
gener
onecycl
virus
use
packag
cell
line
